Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells

Climacteric

Volumn 15, Issue 5, 2012, Pages 467-472

  Ruan, X ^a   Neubauer, H ^b   Yang, Y ^b   Schneck, H ^b   Schultz, S ^b   Fehm, T ^b   Cahill, M A ^c   Seeger, H ^b   Mueck, A O ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Breast Cancer Cells; Progesterone; Progesterone Receptor Membrane Component 1; Proliferation; Synthetic Progestins

Indexed keywords

CHLORMADINONE ACETATE; DESOGESTREL; DROSPIRENONE; DYDROGESTERONE; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEMBRANE PROTEIN; NOMEGESTROL; NORETHISTERONE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EXPRESSION VECTOR; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL MEMBRANE; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMANS; MCF-7 CELLS; MEDROXYPROGESTERONE ACETATE; MEMBRANE PROTEINS; NORETHINDRONE; PROGESTERONE; PROGESTERONE CONGENERS; PROGESTINS; RECEPTORS, PROGESTERONE; TRANSFECTION;

EID: 84858074336     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2011.648232     Document Type: Article

References (31)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefi ts of estrogen plus progestin in healthy post-menopausal women. JAMA 2002;288:321-333
2. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-12
3. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57
4. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-11 (Pubitemid 350179584)
5. Schoonen WGEJ, Joosten JWH, Kloosterboer HJ. Effects of two classes of progestins, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells. 1. MCF-7 cell lines. J Steroid Biochem Mol Biol 1995;55:423-37
6. Cappelletti V, Miodini P Fioravanti L, DiFronzo G. Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines. Anticancer Res 1995;15:2551-6
7. Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO. The effect of progesterone, testosterone and synthetic progesto-gens on growth factor-and estradiol-treated human cancerous and benign breast cells. Eur J Obstet Gynecol Reprod 2006;27: 139-41
8. Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993;67:945-52 (Pubitemid 23147484)
9. Franke HR, Vermes I. Differential effects of progestogens on breast cancer cell lines. Maturitas 2003;46(Suppl 1):S55-8 (Pubitemid 37506063)
10. Cahill MA. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 2007;105:16-36 (Pubitemid 47211947)
11. Meyer C, Schmid R, Scriba PC, Wehling M. Purifi cation and partial sequencing of high-affi nity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem 1996;239:726-33
12. Munton RP, Tweedie-Cullen R, Livingstone-Zatchej M, et al. Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations. Mol Cell Proteomics 2007;6:283-93 (Pubitemid 46359516)
13. Ahmed IS, Rohe HJ, Twist KE, Craven RJ. PGRMC1 (progesterone receptor membrane component 1) associates with EGFR and regulates erlotinib sensitivity. Biol Chem 2010;285:24775-82
14. Neubauer H, Clare SE, Wozny W, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008, 10: R85
15. Neubauer H, Chen R, Schneck H, et al. New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Clin Invest 2011;6:185-92
16. Mueck AO, Seeger H. The role of progestogens in breast cancer: experimental vs. clinical data. Menopausal Med 2006;14:1-6
17. Seeger H, Mueck AO. HRT and breast cancer caused by pro-gestogens? Experimental vs. clinical data. J Steroid Biochem Molecular Biol 2008;109:11-15
18. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169-78 (Pubitemid 43231449)
19. Sitruk-Ware R. Pharmacological profi le of progestins. Maturitas 2004;47:277-83
20. Kuhl H. Pharmacology of estrogens and progestogens: infl uence of different routes of administration. Climacteric 2005;8(Suppl 1): 3-63 (Pubitemid 41232429)
21. Neubauer H, Adam G, Seeger H, et al. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric 2009;3:230-9
22. Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of pro-gestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992;52:6539-56
23. Seeger H, Wallwiener D, Mueck AO. The effect of progesterone and synthetic progestins on serum-and estradiol-stimulated proliferation of human breast cancer cells. Horm Metab Res 2003; 35:76-80 (Pubitemid 36583677)
24. Mueck AO, Seeger H, Wallwiener D. Comparison of the prolif-erative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric 2004;6:221-7 (Pubitemid 37188282)
25. Ebeling K, Ray R, Nischan P, Thomas DB. Kunde D, Stalsberg H. Combined oral contraceptives containing chlormadinone acetate and breast cancer: results of a case-control study. Br J Cancer 1991;63:804-8
26. Nischan P, Ebeling K. Oral contraceptives containing chlormadi-none acetate and cancer incidence at selected sites in the German Democratic Republic-a correlation analysis. Int J Cancer 1984; 34:671-4 (Pubitemid 15207009)
27. Persson I, Yuan J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-32 (Pubitemid 26274121)
28. Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995;55:239-46
29. Botella J, Duranti E, Duc I, Cognet AM, Delansorne R, Paris J. Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. J Steroid Biochem Mol Biol 1994; 50:41-7
30. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in post-menopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65-73
31. Chu MC, Zhang X, Gentzschein E, Stanczyk FZ, Lobo RA. Formation of ethinyl estradiol in women during treatment with nore-thindrone acetate. J Clin Endocrinol Metab 2007;92:2205-7 (Pubitemid 46997123)